Manager TitleAgeSince
Chief Executive Officer 58 2021-08-31
President 58 -
Director TitleAgeSince
Director/Board Member 58 2021-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
11/9/23 Others 101,010 0.0188%
11/9/23
a16z Capital Management LLC
TenderCompany 59,695,246 11.1045%
11/9/23 Exercice

Chief Executive Officer

16,136,833 3.0018%
Change 5-day change 1-year change 3-year change Capi.($)
-2.09%-.--% - - 1.14B
+0.22%+0.07%-1.90%+8.24% 45.81B
-4.36%-5.66%+338.30%+516.88% 43.91B
-0.32%+4.61%+43.90%+26.98% 44.39B
+0.46%-0.83%+6.38%+73.76% 39.4B
-0.17%-3.22%+10.29%+38.69% 31.26B
+3.30%-5.03% - - 15.75B
-0.65%+5.14%+25.61%+120.17% 17.32B
+1.66%+5.30%+19.25%+34.93% 14.73B
+0.19%-1.77%+80.35%+31.52% 13.03B
Average -0.18%-0.94%+65.27%+106.40% 29.51B
Weighted average by Cap. -0.44%-0.87%+76.30%+125.65%
Logo EQRx, Inc.
EQRx, Inc. is a pharmaceutical company. The Company is engaged in developing medicines for some of the prevalent disease areas, including cancer and immune-inflammatory conditions. The Company brands include EQRx and Remaking Medicine. The Company's pipeline is comprised of approximately 10 programs, including both small molecules and biologics, with five clinical-stage programs, and several disclosed and undisclosed preclinical and drug engineering programs. Its clinical programs include Aumolertinib (EQ143), Lerociclib (EQ132), and Sugemalimab (EQ165). Aumolertinib (EQ143) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lerociclib (EQ132) is a novel and oral small molecule cyclin-dependent kinase (CDK) 4/6 inhibitor. Sugemalimab (EQ165, also known as CS1001) is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody.
Employees
362
  1. Stock Market
  2. Stocks
  3. EQRX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!